Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of YL205 in advanced solid tumors
CTR20241918Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL205 in Nonhematologic neoplasms, ovarian cancer, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), sponsored by MediLink Therapeutics. Started Jun 2024; status: active.
02
Drugs
YL205
03
Conditions
Nonhematologic neoplasmsovarian cancerrenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20241918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241918.